Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2014 | 1 |
2021 | 1 |
2022 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5.
N Engl J Med. 2022.
PMID: 36342113
Clinical Trial.
Synthetic DNA spike-ins (SDSIs) enable sample tracking and detection of inter-sample contamination in SARS-CoV-2 sequencing workflows.
Lagerborg KA, Normandin E, Bauer MR, Adams G, Figueroa K, Loreth C, Gladden-Young A, Shaw BM, Pearlman LR, Berenzy D, Dewey HB, Kales S, Dobbins ST, Shenoy ES, Hooper D, Pierce VM, Zachary KC, Park DJ, MacInnis BL, Tewhey R, Lemieux JE, Sabeti PC, Reilly SK, Siddle KJ.
Lagerborg KA, et al.
Nat Microbiol. 2022 Jan;7(1):108-119. doi: 10.1038/s41564-021-01019-2. Epub 2021 Dec 14.
Nat Microbiol. 2022.
PMID: 34907347
Free PMC article.
Item in Clipboard
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.
Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Litzow M, Gabrilove J, Erba HP, Gore SD, Tallman MS.
Prebet T, et al.
J Clin Oncol. 2014 Apr 20;32(12):1242-8. doi: 10.1200/JCO.2013.50.3102. Epub 2014 Mar 24.
J Clin Oncol. 2014.
PMID: 24663049
Free PMC article.
Clinical Trial.
DESIGN: Open label phase II randomized trial comparing AZA 50 mg/m(2)/d given for 10 days entinostat 4 mg/m(2)/d day 3 and day 10. ...
DESIGN: Open label phase II randomized trial comparing AZA 50 mg/m(2)/d given for 10 days entinostat 4 mg/m(2)/d day 3 and day …
Item in Clipboard
Cite
Cite